Last updated: November 2, 2026
LILETTA is a 52-mg levonorgestrel-releasing intrauterine system commercialized in the United States by AbbVie following its acquisition of Allergan. Medicines360 developed the product and retains its nonprofit-centered commercial model. The product competes directly with Bayer’s Mirena and indirectly with other long-acting reversible contraceptives, including Kyleena, Skyla, Paragard and Nexplanon.
LILETTA’s commercial position improved materially after FDA extensions increased contraceptive duration from three years to eight years. Its principal constraints are procedure-based access, reimbursement complexity, provider supply, competition from Mirena, and the absence of publicly reported standalone sales.
What is LILETTA and how does it work?
LILETTA is a levonorgestrel-releasing intrauterine system indicated for:
- Prevention of pregnancy for up to eight years
- Treatment of heavy menstrual bleeding for up to five years in patients who choose intrauterine contraception
The product releases levonorgestrel locally in the uterus. Its contraceptive effect is based primarily on thickening cervical mucus, inhibiting sperm movement and function, and altering the endometrium. LILETTA is a drug-device combination product reviewed under FDA New Drug Application No. 203159.[1]
The system contains 52 mg of levonorgestrel. Its closest branded comparator is Mirena, which also contains 52 mg of levonorgestrel and has an eight-year contraceptive duration. The products differ in device design, labeling history, commercial ownership and pricing arrangements.
When did LILETTA receive FDA approval and exclusivity extensions?
LILETTA was initially approved by the FDA in February 2015 for prevention of pregnancy for up to three years.[1] Subsequent regulatory actions expanded the product’s duration and indications.
| FDA milestone |
LILETTA regulatory development |
| February 2015 |
Initial approval for contraception for up to three years |
| 2018 |
Contraceptive duration extended to four years; heavy menstrual bleeding indication added |
| 2020 |
Contraceptive duration extended to six years |
| 2022 |
Contraceptive duration extended to seven years |
| 2023 |
Contraceptive duration extended to eight years |
| Current labeling |
Eight years for contraception; five years for heavy menstrual bleeding |
The duration extensions increased the product’s value proposition without requiring a new insertion for patients who otherwise would have replaced the device earlier. They also reduced annualized treatment cost when measured over the full labeled duration.
The regulatory extensions were based on clinical follow-up data rather than a new active ingredient. The principal commercial effect was an increase in product utility and a stronger position against shorter-duration contraceptive methods.[2]
What companies market LILETTA?
Medicines360 developed LILETTA as a nonprofit organization focused on expanding access to intrauterine contraception. Allergan entered into a commercialization agreement with Medicines360 before the product’s launch. AbbVie assumed Allergan’s rights after completing its acquisition of Allergan in 2020.[3]
| Company |
Role |
| Medicines360 |
Developer and originator organization |
| Allergan |
Original U.S. commercial partner |
| AbbVie |
Current U.S. commercial partner following the Allergan acquisition |
| FDA |
Regulator for the drug-device combination product |
LILETTA’s commercial structure differs from a conventional pharmaceutical product because product economics depend on the relationship between the originator organization, commercial partner, public-sector pricing and provider reimbursement.
How large is the LILETTA market?
LILETTA operates within the U.S. long-acting reversible contraception market. The market includes hormonal intrauterine systems, copper intrauterine devices and subdermal implants.
Demand is supported by several factors:
- Long duration and low user burden.
- High contraceptive effectiveness.
- Greater clinician and patient familiarity with intrauterine systems.
- Public-sector purchasing and family-planning programs.
- Expanded contraceptive access priorities after changes in U.S. abortion policy.
- Use of the product for both contraception and heavy menstrual bleeding.
The category also has structural limitations. Insertion requires a trained healthcare professional. Patients may face appointment delays, out-of-pocket costs, device availability problems and concerns about insertion-related pain. These barriers make market growth dependent on clinical capacity, reimbursement and distribution as well as patient demand.
LILETTA’s eight-year indication strengthens its competitive economics. A device with a longer labeled life can reduce replacement frequency, although providers and payers do not always translate that benefit into a lower acquisition price.
What are LILETTA’s sales and financial trajectory?
AbbVie does not publicly report standalone LILETTA revenue, unit volume, gross margin or profitability. The product is included within broader reporting categories or is not separately identified in public financial disclosures. As a result, an exact LILETTA revenue trajectory cannot be established from AbbVie’s annual reports alone.
The available financial interpretation is directional:
- LILETTA had a launch-stage growth profile after its 2015 approval.
- FDA duration extensions improved lifetime product value and supported replacement-cycle economics.
- The product benefits from recurring demand because each device must eventually be removed and replaced, although an eight-year label lengthens the replacement interval.
- Revenue is exposed to public-sector pricing, Medicaid reimbursement, commercial insurance coverage and provider purchasing decisions.
- Standalone LILETTA sales are immaterial to AbbVie’s consolidated revenue compared with immunology, oncology, aesthetics and neuroscience products.
- The product’s strategic value is greater than its disclosed revenue contribution because it supports AbbVie’s women’s health portfolio and provides exposure to a durable contraceptive category.
AbbVie’s public financial reporting does not provide a reliable basis for calculating LILETTA’s annual revenue, market share or product-level operating margin. Any model assigning a precise figure to LILETTA sales would depend on third-party prescription, procedure, shipment or channel data rather than audited AbbVie disclosure.
How does LILETTA compare with Mirena, Kyleena and other contraceptives?
| Product |
Active ingredient |
Device type |
Contraceptive duration |
Heavy menstrual bleeding indication |
Commercial owner |
| LILETTA |
Levonorgestrel, 52 mg |
Hormonal IUS |
Up to 8 years |
Up to 5 years |
AbbVie/Medicines360 |
| Mirena |
Levonorgestrel, 52 mg |
Hormonal IUS |
Up to 8 years |
Up to 5 years |
Bayer |
| Kyleena |
Levonorgestrel, 19.5 mg |
Hormonal IUS |
Up to 5 years |
No corresponding labeled indication |
Bayer |
| Skyla |
Levonorgestrel, 13.5 mg |
Hormonal IUS |
Up to 3 years |
No corresponding labeled indication |
Bayer |
| Paragard |
Copper |
Nonhormonal IUD |
Up to 10 years |
No |
CooperSurgical |
| Nexplanon |
Etonogestrel |
Subdermal implant |
Up to 5 years under current FDA labeling |
No |
Organon |
LILETTA’s closest commercial comparison is Mirena. Both products have the same levonorgestrel content and an eight-year contraceptive label. Mirena has earlier market entry, stronger brand recognition and a longer history of use for heavy menstrual bleeding. LILETTA has competed through access-oriented pricing, public-sector availability and a differentiated nonprofit development model.
Kyleena and Skyla target patients seeking smaller or lower-dose hormonal systems. Paragard appeals to patients seeking nonhormonal contraception. Nexplanon competes on duration and efficacy but requires a subdermal insertion rather than an intrauterine procedure.[4]
What patents protect LILETTA?
LILETTA’s protection is based on a combination of product, device, formulation, manufacturing and method-of-use rights rather than on a new chemical entity patent for levonorgestrel.
Potential protection categories include:
- The intrauterine delivery system
- The polymer reservoir and drug-release structure
- Drug loading and release characteristics
- Device geometry and placement components
- Manufacturing and assembly processes
- Use for contraception
- Use for treatment of heavy menstrual bleeding
The exact Orange Book patent listing and expiration analysis must be conducted against the current FDA Orange Book record for NDA 203159. Publicly available materials do not establish a single, commercially decisive LILETTA patent expiration date comparable to a small-molecule composition-of-matter expiry.
This distinction matters. For a complex drug-device product, a generic or follow-on entrant may need to address not only listed patents but also manufacturing reproducibility, device equivalence, clinical performance and FDA approval requirements.
What is the Orange Book status of LILETTA?
LILETTA is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under NDA 203159.[5]
The product is a combination of:
- A levonorgestrel active pharmaceutical ingredient
- A polymeric intrauterine delivery device
- A controlled-release drug reservoir
- A clinical insertion and removal system
The Orange Book status is commercially relevant because it identifies patents and regulatory exclusivities that an abbreviated new drug application applicant may need to address. The existence of an Orange Book listing does not by itself prevent competition after patent expiry. An ANDA applicant can challenge listed patents through a Paragraph IV certification or wait for the relevant patent barriers to expire.
Are there Paragraph IV challenges or approved generic versions of LILETTA?
No approved generic version of LILETTA is identified in the public FDA product framework through the available record. There is also no publicly established, commercially material Paragraph IV litigation campaign against LILETTA comparable to the challenges seen for major oral small-molecule products.
A future entrant would face several technical and regulatory barriers:
- Demonstrating pharmaceutical equivalence to the levonorgestrel delivery system.
- Establishing bioequivalence or an FDA-accepted alternative for a locally acting intrauterine product.
- Matching the release profile over the labeled duration.
- Demonstrating device performance and insertion characteristics.
- Addressing Orange Book patents through Paragraph IV, a section viii statement where applicable, or patent expiry.
- Building manufacturing capacity for a specialized drug-device system.
These requirements make immediate generic substitution less likely than in conventional tablets or capsules. The more probable competitive pathway is a complex generic or follow-on intrauterine system supported by device and clinical data.
What formulation and manufacturing barriers affect LILETTA?
LILETTA’s formulation is inseparable from the device. The commercial product must deliver levonorgestrel at a controlled rate over multiple years while maintaining structural integrity and predictable insertion performance.
Key manufacturing barriers include:
- Consistent polymer-drug matrix production
- Long-term release-rate control
- Sterile manufacturing and packaging
- Dimensional consistency of the device
- Reliable attachment of insertion components
- Stability over the full shelf life
- Quality control for a drug-device combination
These barriers can delay a follow-on product even if the active ingredient itself is old and widely available. They also create supply-chain risk because a manufacturing interruption affects a multiyear contraceptive product with limited short-term substitution options.
What patent litigation affects LILETTA?
No major publicly reported patent litigation involving LILETTA has established a near-term generic launch date or settlement-driven entry schedule. There is no widely disclosed settlement agreement that sets a specific authorized generic or competing intrauterine system launch date.
The most relevant litigation risk would arise from:
- A Paragraph IV challenge to Orange Book-listed patents
- A patent dispute involving device architecture or release characteristics
- Manufacturing-process litigation
- Contract disputes involving Medicines360 and its commercial partners
- Antitrust or access litigation involving pricing and distribution
The absence of a public litigation event does not eliminate future challenge risk. It indicates that LILETTA has not generated the same visible generic litigation profile as high-revenue oral drugs with simple dosage forms.
When does LILETTA lose exclusivity?
LILETTA does not have a single clearly disclosed loss-of-exclusivity date that can be used as a definitive generic-entry date. Its initial FDA approval occurred in 2015, but the relevant commercial barriers include patents, regulatory exclusivity, device-specific approval requirements and manufacturing capability.
The product’s exclusivity profile can be summarized as follows:
| Exclusivity factor |
Commercial effect |
| New drug approval |
Provided initial FDA market protection after 2015 approval |
| Drug-device patents |
May limit substantially equivalent intrauterine systems |
| Method-of-use patents |
May affect heavy menstrual bleeding and contraceptive uses |
| Device and process know-how |
Raises entry costs even after patent expiry |
| FDA approval requirements |
May prevent automatic substitution by ordinary generics |
| Public-sector contracting |
Can protect volume but compress net price |
FDA regulatory exclusivity and patent protection should be analyzed separately. A patent expiry does not guarantee immediate competition, and the end of regulatory exclusivity does not eliminate valid patent rights.
What generic launch risks exist for LILETTA?
The near-term generic launch risk appears lower than for a standard oral contraceptive. The main risks are medium-term rather than immediate and include:
- A successful Paragraph IV challenge
- FDA acceptance of a complex generic development pathway
- Entry by a competing hormonal IUD with similar duration
- Price competition from Mirena or other branded systems
- Public-sector purchasing shifts
- New lower-cost products supported by nonprofit or government programs
A generic entrant would probably compete first in price-sensitive Medicaid, family-planning and institutional channels. Commercial insurers may continue to reimburse the branded product if provider familiarity and supply reliability remain stronger.
What is LILETTA’s competitive and commercial outlook?
LILETTA’s commercial outlook is stable to moderately positive, with growth driven by category demand rather than a new mechanism of action. The eight-year contraceptive label supports patient convenience and improves product economics over the treatment life. The heavy menstrual bleeding indication broadens the addressable population beyond contraception.
The main commercial risks are:
- Mature-category competition from Mirena
- Limited provider capacity for insertion
- Reimbursement and prior-authorization friction
- Public-sector price compression
- Long replacement intervals that reduce recurring unit demand
- Potential follow-on IUD development
- Lack of standalone financial transparency
For AbbVie, LILETTA is unlikely to become a major consolidated revenue driver. Its value lies in recurring participation in a durable contraceptive market, portfolio breadth in women’s health and access to a product with meaningful public-sector demand.
How strong is the LILETTA patent estate?
LILETTA’s patent estate is best characterized as moderate when assessed against the product’s complex device and formulation requirements, but less dominant than a strong composition-of-matter estate.
Strengths include:
- Integrated drug-device design
- Controlled-release formulation
- Manufacturing complexity
- Long clinical history
- Multiple potential protection categories
Limitations include:
- Levonorgestrel is an established active ingredient
- Mirena provides a direct same-dose branded comparator
- A complex generic pathway may eventually become feasible
- Standalone patent expiration data are not sufficient to forecast a precise launch date
The practical barrier to entry is therefore a combination of intellectual property, regulatory science and manufacturing execution.
Key Takeaways
- LILETTA is a 52-mg levonorgestrel intrauterine system approved for eight years of contraception and five years of heavy menstrual bleeding treatment.
- AbbVie commercializes the product after acquiring Allergan; Medicines360 remains the originating organization.
- LILETTA competes most directly with Bayer’s Mirena.
- FDA duration extensions have improved lifetime product value and reduced the frequency of device replacement.
- AbbVie does not disclose standalone LILETTA revenue, units or margin.
- No approved generic LILETTA product or major public Paragraph IV launch settlement is established in the available record.
- The main barriers to competition are device equivalence, controlled release, sterile manufacturing, FDA requirements and patent review.
- LILETTA’s financial importance is strategic and portfolio-based rather than material to AbbVie’s consolidated revenue.
- Generic-entry risk is lower in the near term than for conventional oral contraceptives but could increase as complex intrauterine development advances.
FAQs About LILETTA Patents, Sales and Competition
Is LILETTA the same as Mirena?
No. Both contain 52 mg of levonorgestrel and have an eight-year contraceptive indication, but they are separate branded products with different device designs, ownership histories and commercial agreements.
Does LILETTA generate revenue for AbbVie?
Yes, AbbVie commercializes LILETTA, but the company does not publicly disclose a standalone LILETTA revenue line in its principal financial reports.
Can a pharmacy automatically substitute a generic for LILETTA?
No approved generic LILETTA product is established in the public FDA record. Intrauterine systems also require insertion by a healthcare professional, so substitution economics differ from oral generic drugs.
Is LILETTA covered by Medicaid?
Coverage varies by state program, managed-care arrangement and provider channel. LILETTA has been positioned for public-sector access, but reimbursement and acquisition terms determine actual availability.
What is the main risk to LILETTA sales?
The principal risk is competitive and reimbursement pressure rather than rapid generic substitution. Mirena, public-sector pricing, provider capacity and future complex-IUD entrants are the most relevant commercial factors.
References
- U.S. Food and Drug Administration. (2015). LILETTA prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2023). FDA approves expanded duration of use for LILETTA intrauterine device. https://www.fda.gov
- AbbVie Inc. (2020). AbbVie completes acquisition of Allergan. https://news.abbvie.com
- Centers for Disease Control and Prevention. (2024). U.S. selected practice recommendations for contraceptive use. https://www.cdc.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov
